Clinical trials: Sitagliptin, completed
Healthy
Bioavailability of BI 10773 and Sitagliptin in Healthy Male Volunteers
The objective was to investigate whether there was a drug-drug interaction between BI 10773 and sitagliptin when co-administered as multiple oral doses.
- Trial name
- NCT02172196
- Testing
- BI 10773, Sitagliptin
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)
The purpose of this study is to test the safety and effectiveness of sitagliptin in patients with type 2 diabetes.
- Trial name
- NCT00541775
- Testing
- Sitagliptin, Comparator: Rosiglitazone, Comparator: Metformin
- Volunteers
- 273 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Heart Failure
The Effects of Neprilysin on Glucagon-like Peptide-1
In the current study we wish to investigate the effects on glucagon-like peptide-1 (GLP-1) of a neprilysin inhibitor
- Trial name
- NEP (NCT03717688)
- Testing
- Entresto, Sitagliptin 100mg
- Where
- Denmark
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Nicolai Jacob Wewer Albrechtsen
Healthy
Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed)
Crossover study to compare the pharmacokinetic characteristics of GLH1SM sustained release tablet and Janumet XR tablet in fed condition
- Trial name
- NCT03927170
- Testing
- Janumet XR tablet 100/1000 mg, GLH1SM tablet 100/1000 mg
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GL Pharm Tech Corporation
Bioequivalence, Diabetes Mellitus, Type 2
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.
The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose…
- Trial name
- NCT06124573
- Testing
- Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
- Where
- Mexico
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Galenicum Health
Healthy, Pharmacokinetics of ASP1941
A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects
The purpose of the study is to evaluate pharmacokinetics, pharmacodynamics and safety following the administration of ASP1941 and sitagliptin in single and multiple doses.
- Trial name
- NCT01104532
- Testing
- ASP1941, sitagliptin
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Gastroparesis, Diabetes Mellitus
Effects of Sitagliptin on Gastric Emptying in Healthy Subjects
The purpose of this study is to determine the effects of the drug, sitagliptin, on the rate at which the stomach empties, and the release of gut hormones and blood glucose concentrations, after a mashed potato meal in healthy…
- Trial name
- NCT00501657
- Testing
- Sitagliptin
- Where
- Australia
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Royal Adelaide Hospital
Healthy Volunteers
A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.
The objective of this study is to assess the effect of repeated doses of ABBV-722 on the single dose pharmacokinetics (PK) of Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin
- Trial name
- NCT07567781
- Testing
- ABBV-722, Midazolam, Metformin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AbbVie
Type II Diabetes
Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
This study is a three part study to assess the safety and efficacy of LEZ763 on normal healthy volunteers and patients with Type 2 Diabetes.
- Trial name
- NCT01619332
- Testing
- Sitagliptin, LEZ763
- Where
- 6 sites in United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Liver Cirrhosis With Diabetes
Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis
This study was a prospective, interventional, two-part pilot clinical study conducted over 3 months on cirrhotic patients with diabetes mellitus and diabetic neuropathy, evaluating the real-world applicability of selected…
- Trial name
- NCT07439536
- Testing
- Sitagliptin (Januvia), Sitagliptin (JANUVIA®), Duloxetine (60 mg) once daily
- Where
- Egypt
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Kafrelsheikh University
Type 2 Diabetes Mellitus
Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects
To assess the effect of glimepiride on the PK of dapagliflozin and the effect of dapagliflozin on the PK of glimepiride, when co-administered in healthy subjects (Phase A) and to assess the effect of sitagliptin on the PK of…
- Trial name
- NCT00842556
- Testing
- Dapagliflozin, Glimepiride, Sitagliptin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Bioequivalence, Diabetes Mellitus, Type 2
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.
The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose…
- Trial name
- NCT06124560
- Testing
- Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
- Where
- Mexico
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Galenicum Health
Diabetes Mellitus, Type 2
A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes
The purpose of Part A of this study is to test whether repeated doses of the study drug (GSK1614235) are safe and well tolerated (i.e.
- Trial name
- SGA112534 (NCT00976261)
- Testing
- GSK1614235, Sitagliptin
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Subjects
A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of SID1903 and SID1903-R1/SID1903-R2 in healthy adult volunteers.
- Trial name
- NCT05453786
- Testing
- SID1903, SID1903-R1/SID1903-R2
- Where
- South Korea
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Obesity
Effect of DPP4 Inhibition on Growth Hormone Secretion
This study tests the following hypotheses: Aim 1: Test the hypothesis that acute dipeptidyl peptidase 4 (DPP4) inhibition with the currently available anti-diabetic drug, sitagliptin, will increase stimulated growth hormone (GH)…
- Trial name
- NCT01701973
- Testing
- Sitagliptin, Pegvisomant, L-NMMA
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Diabetes Mellitus
SNP Study of DPP-4 and GLP-1R in Chinese People (Including Diabetes Patients)
Incretin-based therapy is currently one of the most popular diabetes treatment approaches. However, differences of response ware found in previous studies.
- Trial name
- NCT03108521
- Testing
- Sitagliptin
- Where
- China
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Sichuan Provincial People's Hospital
Diabetes Mellitus, Type 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin
This study will assess the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and pharmacodynamics (explores what a drug does to the body) of single doses of JNJ-38431055, sitagliptin, and…
- Trial name
- NCT01054118
- Testing
- JNJ-38431055, Sitagliptin 100 mg, JNJ-38431055 + Sitagliptin 100 mg
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus Type 2
CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)
The purpose of this study is to evaluate a pharmacokinetic drug interaction between sitagliptin and lobeglitazone in healthy male volunteers.
- Trial name
- NCT02827890
- Testing
- Januvia Tab. 100mg, Januvia Tab. 100mg + Duvie Tab. 0.5mg
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Bioequivalence, Diabetes Mellitus, Type 2
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.
The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose…
- Trial name
- NCT06124495
- Testing
- Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet
- Where
- Mexico
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Galenicum Health
Healthy
The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology
The purpose of this study is to determine the pharmacogenetics, pharmacokinetics, and drug-drug interactions of sitagliptin therapy.
- Trial name
- NCT01112670
- Testing
- Sitagliptin, atorvastatin
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver